NCT00115154

Study to Assess the Safety and Efficacy of Imiquimod 5% Cream for the Treatment of Actinic Keratosis on the Arms and Hands

Vehicle-Controlled, Double-Blind Study to Assess the Safety and Efficacy of Imiquimod 5% Cream for the Treatment of Actinic Keratosis on the Upper Extremities

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 270 (planned)
• Sponsor: Graceway Pharmaceuticals, LLC · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate the safety and efficacy of imiquimod 5% cream compared to vehicle cream in the treatment of Actinic Keratosis (AK) on the arm and/or hand when the cream is applied once daily 2 days per week for 16 weeks.

Conditions

• Keratosis

Interventions

Type	Name	Description
DRUG	Aldara (imiquimod) cream, 5%

Timeline

• Start date: 2005-05-01
• Completion: 2006-09-01
• First posted: 2005-06-22
• Last updated: 2007-02-19

Locations

18 sites across 1 country: United States